Tagged with EG

Pharma Legal Handbook All legal aspects surrounding regulatory, pricing and reimbursement in Estonia. Prepared in association with TGS Baltic, a leading law firm in Estonia, this is an extract from The Pharma Legal Handbook: Baltics, available to purchase here for GBP 99.   1. What are the regulatory authorities with jurisdiction over drugs,…

Turkey Okan Güner of Viatris Turkey introduces the company’s sizeable footprint in the country, including local manufacturing and explains the challenges of executing an integration of two companies during the COVID-19 pandemic. Güner outlines Viatris’ role within Turkey’s Vision 2023, the opportunities for their biosimilars pipeline, and their portfolio’s role in…

Denmark Erik Jylling of the Danish Regions, the organisation charged with healthcare management for each of Denmark’s five regions, outlines the advantages and challenges which persist within Danish healthcare and sounds a clarion call for faster adaptation and greater collaboration with private industry.   The innovation power that private enterprises have…

Turkey Although best known for its food and beverage operations, Nestlé also has a Health Science business that generates approximately USD 3 billion annually for the Swiss conglomerate. Hanzade Yaz, General Manager of Nestlé Health Science Turkey, discusses the affiliate’s leading position in medical nutrition, portfolio expansion following recent global acquisitions…

Saudi Arabia Recently appointed CEO of Saudi Chemical Company Holding’s Pharma Sector, Ismail Shehada is today drawing on 20+ years of Big Pharma experience to drive SCCH’s growing life sciences footprint in alignment with the Kingdom of Saudi Arabia’s Vision 2030 healthcare transformation. Shehada explains how SCCH is moving into third-party logistics…

Korea Amid global supply shortages and shipment delays for COVID-19 vaccines, South Korea has launched an ambitious 2.2 trillion won (USD 1.9 billion) investment plan to become one of the world’s five largest COVID-19 vaccine manufacturing hubs by 2025. Here, we provide a rundown of some of the key companies involved…

Switzerland Barbara Fritsche-Surchat outlines Servier’s historic commitment to Switzerland, how the French mid-cap’s global oncology pivot is translating into its Swiss operations, and comments on the evolution of pharma salesforces post-pandemic.   Over the years, we have developed a real expertise, predominantly in the cardiovascular field, but we will leverage this…

Saudi Arabia Aspen’s regional CEO for the Middle East, North Africa & Turkey, Daniel Vella Friggieri, provides insights into how the South African company’s federated model and decentralized management system translates into differentiated portfolios across regions and significant networks of local CMO partners. After more than five years with Aspen in the…

Turkey Ercin Kugu, CSL Behring’s general manager for Turkey and Israel, highlights the rare disease company’s footprint in Turkey, explains the different regulatory framework in the country for plasma products, and provides insights on the process of establishing Big Pharma affiliates in Turkey from zero after doing so for both Shire…

Japan Writing in the October edition of DIA’s Global Forum magazine, Chief Executive of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Yasuhiro Fujiwara outlines how his agency has begun to utilise real-world data (RWD) and real-world evidence (RWE) in its regulatory decision-making processes and how this will evolve moving forward.  …

Denmark Danish pharma industry veteran Peter Drøidal highlights how he steered the Danish Novartis affiliate through the COVID-19 pandemic period, the strategy in place to navigate an increasingly challenging market access landscape, and the lessons that can be leveraged from the value-based agreement that Novartis was able to strike with the…

Saudi Arabia Prof. Ahmed Aljedai, assistant deputy minister of therapeutic affairs for support services at Saudi Arabia’s Ministry of Health (MoH) outlines how the Saudi healthcare system is being restructured in line with the country’s Vision 2030 economic transformation programme and the three goals of improving access, improving quality, and improving value.…